ENMD-1198 is a potent, orally-active, internally discovered antimitotic agent that causes cell cycle arrest and apoptosis in tumor cells. ENMD-1198 has shown pronounced antitumor activity and survival increases in multiple preclinical models, including a substantial decrease in tumor cell proliferation and angiogenesis in a breast cancer model; synergistic effects in combination with vincristine that prolonged survival in preclinical leukemia models; and a three-fold increase in survival compared to standard-of-care Cisplatin in a preclinical NSCLC model.

ENMD-1198 does not exhibit sensitivity to multi-drug resistance mechanisms in preclinical studies. ENMD-1198 also has shown preclinical activity in taxane and vinca alkaloid resistant tumor cells. Additionally, ENMD-1198 decreases the activity of three oncogenic proteins (HIF-1α, NF-κB and STAT3) that are known to promote tumor growth and progression.

Once daily, oral administration of ENMD-1198 is currently being evaluated in a Phase 1 clinical trial for safety, tolerability, pharmacokinetics, and clinical benefit in advanced cancer patients. Please visit the Clinical section of our website for further Clinical Trial information.